NBIX vs NGNE · P/E 45, rev $1.77B vs $286.5M cap
Neurocrine Biosciences Inc (NBIX) versus Neurogene Inc (NGNE) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Neurogene Inc (NGNE) is a biotechnology company listed on US.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported NGNE revenue for 2025-09-30 was $0. Net income was -$21.0M. NGNE currently screens at market cap $286.5M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. NGNE currently screens at market cap $286.5M.
Not investment advice. Open the NBIX and NGNE stock pages for the full models.
Not investment advice.